Aethlon Medical (NASDAQ:AEMD – Get Free Report) is projected to announce its Q4 2025 earnings results before the market opens on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
Aethlon Medical Stock Down 1.7%
NASDAQ AEMD opened at $1.74 on Thursday. The company has a 50-day simple moving average of $2.84 and a two-hundred day simple moving average of $3.82. Aethlon Medical has a 12-month low of $1.66 and a 12-month high of $8.44. The firm has a market cap of $3.50 million, a price-to-earnings ratio of -0.14 and a beta of 1.89.
Analyst Upgrades and Downgrades
AEMD has been the subject of a number of research reports. Wall Street Zen initiated coverage on shares of Aethlon Medical in a research note on Thursday, May 15th. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $56.00 target price on shares of Aethlon Medical in a research note on Monday, March 10th.
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Featured Articles
- Five stocks we like better than Aethlon Medical
- How to Use Stock Screeners to Find Stocks
- Chime’s Smart IPO: Half the Valuation, Double the Strength
- How to Invest in Biotech Stocks
- Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
- About the Markup Calculator
- 3 Catalysts in 7 Days: Archer’s Growth Story Just Accelerated
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
